Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses

This publication has 29 references indexed in Scilit:

• Inhibition of human monocyte TNF production by adenosine receptor agonists
  Life Sciences, 1993
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
  Arthritis & Rheumatism, 1993
• Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
  European Journal of Immunology, 1993
• The Pathophysiology of Tumor Necrosis Factors
  Annual Review of Immunology, 1992
• Modulation of tumor necrosis factor release from alveolar macrophages treated with pentamidine isethionate
  International Journal of Immunopharmacology, 1992
• Pentamidine blocks the pathophysiologic effects of endotoxemia through inhibition of cytokine release
  Toxicology and Applied Pharmacology, 1992
• Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.
  The Journal of Experimental Medicine, 1990
• Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality
  Life Sciences, 1989
• Cyclosporine a inhibits TNF production without decreasing TNF mRNA levels
  Biochemical and Biophysical Research Communications, 1989
• Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline
  Biochemical and Biophysical Research Communications, 1988